Cempra, Inc. (Nasdaq: CEMP) announced interim results showing anti-NASH effects in the first six nonalcoholic steatohepatitis (NASH) patients dosed with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE